Abbvie stock has been an excellent performer since its spin off from Abbott. It has over tripled since 2014 and it pays a nice 3.5% dividend, growing at a good rate, making it a great investment for passive income or growth. Is this dividend sustainable going forward? Will Humira biosimilars but the dividend under pressure.
Disclaimer: This is not personalised financial advice and should not be taken as such. If you require personalised advice please consult a professional financial advisor.